Reply
- PMID: 39047135
- PMCID: PMC11282323
- DOI: 10.1097/IAE.0000000000004134
Reply
Abstract
We wrote the letter in response to the insightful comments made by Dr. Vassallo J regarding our recently published study, “Association of Oral Montelukast with Reduced Odds of Developing Exudative Age-Related Macular Degeneration.” Our study underscored the potential treatment for AMD through managing mast cell activation.
Comment on
-
ASSOCIATION OF ORAL MONTELUKAST WITH REDUCED ODDS OF DEVELOPING EXUDATIVE AGE-RELATED MACULAR DEGENERATION.Retina. 2023 Nov 1;43(11):1914-1921. doi: 10.1097/IAE.0000000000003870. Retina. 2023. PMID: 37339446
References
-
- Matsumiya W, Karaca I, Pham BH et al. ASSOCIATION OF ORAL MONTELUKAST WITH REDUCED ODDS OF DEVELOPING EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina 2023; 43:1914–1921. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
